Multiple sclerosis in US minority populations
Clinical practice insights
Citation Manager Formats
Make Comment
See Comments

Article Information
- First Published January 16, 2015.
Article Versions
- Previous version (January 16, 2015 - 13:00).
- You are viewing the most recent version of this article.
Author Disclosures
- Omar Khan, MD,
- Mitzi J. Williams, MD,
- Lilyana Amezcua, MD,
- Adil Javed, MD, PhD,
- Kristin E. Larsen, PhD and
- Jennifer M. Smrtka, NP
- Omar Khan, MD,
Teva Pharmaceuticals, Biogen Idec, National MS Society, Genentech/Roche
NONE
Teva Pharmaceuticals, Novartis, Biogen Idec
Journal of Neurological Sciences, member Editorial Board.
NONE
NONE
NONE
Teva Pharmaceuticals, Novartis, Biogen Idec, EMD Serono, Roche, Genzyme, Questcor
Teva Pharmaceuticals, Novartis, Biogen Idec
NONE
NONE
Teva Pharmaceuticals, Novartis, Biogen Idec, Genzyme, Roche
NIH
NONE
National MS Society, DMC Foundation, Sastry Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Mitzi J. Williams, MD,
1. Biogen Idec 2. TEVA Neuroscience 3. Bayer 4. Questcor Pharmaceuticals, 5. EMD Serono 6. Pfizer 7. Novartis
NONE
1. Biogen Idec - speaker bureau, travel to speaker training and consultant meetings 2. TEVA Neuroscience - speaker bureau, travel to speaker training and consultant meetings 3. Bayer - speaker bureau, travel to speaker training and consultant meetings, Sales meeting professional panel 5. Questcor Pharmaceuticals - speaker bureau, travel to speaker training and consultant meetings 6. EMD Serono -speaker bureau, travel to speaker training and consultant meetings, 7. Pfizer - speaker bureau, 8. Novartis - speaker bureau, travel to speaker training and consultant meetings, Medical science liason training 9. Accorda- travel to speaker training
NONE
NONE
NONE
NONE
1. Biogen Idec 2. TEVA Neuroscience 3. Bayer 4. Questcor Pharmaceuticals, 5. Novartis 6. EMD Serono
1. Biogen Idec 2. TEVA Neuroscience 3. Bayer 4. Questcor Pharmaceuticals, 5. EMD Serono 6. Pfizer 7. Novartis 8. Accorda 9. Genzyme
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lilyana Amezcua, MD,
1) Biogen Idec 2) Novartis 3) Acorda
NONE
1) Biogen 2) Novartis 3) Genzyme 4) Acorda
NONE
NONE
NONE
NONE
1) Biogen 2) Novartis 3) Genzyme 4) Acorda 5) TEVA
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Adil Javed, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I have been a consultant for Bayer, Biogen, Questcor, Novartis, and Teva Neuroscience.
I have been a consultant for Bayer, Biogen, Questcor, Novartis, and Teva Neuroscience.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kristin E. Larsen, PhD and
NONE
NONE
NONE
NONE
NONE
NONE
a professional medical writer employed by ProEd Communications, Inc. at the time of manuscript development. Biogen Idec provided funding to ProEd Communications, Inc. for editorial support in the development of this paper.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jennifer M. Smrtka, NP
NONE
NONE
(1) Acorda- speaker honoraria (2) Bayer- speaker honoraria (3) Biogen- travel and speaker honoraria (4)Genzyme- speaker honoraria (5) Novartis- travel and speaker honoraria (6) Pfizer- speaker honoraria (7) Teva- travel and speaker honoraria (8) Questcor-travel and speaker honoraria
NONE
NONE
NONE
NONE
(1) Multiple Sclerosis of America (2) National Multiple Sclerosis Society (3) CAN DO MS (4) Acorda (5) Questcor
(1) Acorda(2) Bayer (3) Biogen (4)Genzyme (5) Novartis (6) Pfizer (7) Teva (8) Questcor
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Department of Neurology (OK), Wayne State University School of Medicine, Detroit, MI; Multiple Sclerosis Center of Atlanta (MJW), GA; Department of Neurology (LA), Keck School of Medicine, University of Southern California, Los Angeles; Department of Neurology (AJ), University of Chicago School of Medicine, IL; ProEd Communications (KEL), Beachwood, OH; and South Florida Neurology Associates (JMS), Boca Raton.
- Correspondence to:
okhan{at}med.wayne.edu
Article usage
The Nerve!: Rapid online correspondence
- LETTER RE: Multiple sclerosis in US minority populations: Clinical practice insights
- Jagannadha Avasarala, MD, PhD, Greenville Health System, Greenville, SCjavasarala@ghs.org
Submitted February 23, 2015
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.